News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Dr. Pol Bamelis Aappointed Devgen NV Board Member
September 25, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ghent, Belgium, September 25, 2006 - Devgen (Euronext Brussels: DEVG) announces today that Dr. Pol Bamelis has been appointed member of the board on September 22nd.
Twitter
LinkedIn
Facebook
Email
Print
People
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH EVOTEC
Strategic Drug Development in a Funding Crisis: Expert Insights on Risk Profiling, Efficiency, and Innovation
October 13, 2025
·
8 min read
·
BioSpace Insights
Drug pricing
AstraZeneca Becomes Second Pharma to Strike DTC Deal With Trump Administration
October 10, 2025
·
1 min read
·
Dan Samorodnitsky
Layoff Tracker
Ferring To Cut 500 Employees as Part of Business Model Shift
October 10, 2025
·
70 min read
·
BioSpace Editorial Staff
Mergers & acquisitions
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover
October 10, 2025
·
2 min read
·
Tristan Manalac
